{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:49:53Z","timestamp":1791319793169,"version":"4.3.1"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hoc.2026.08.005","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:50:41Z","timestamp":1791316241000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Brain Tumor Vaccines"],"prefix":"10.1016","author":[{"given":"Andres","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Antonio","family":"Chiocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.hoc.2026.08.005_bib1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2026.08.005_bib2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(25)00705-3","article-title":"20 years of the stupp protocol: confronting stagnation in glioblastoma therapy","volume":"27","author":"Khasraw","year":"2026","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.08.005_bib3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.adro.2019.03.009","article-title":"Role of radiation therapy in the management of diffuse intrinsic pontine glioma: a systematic review","volume":"4","author":"Gallitto","year":"2019","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.005_bib4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1200\/JCO.1995.13.1.112","article-title":"Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen, Childrens Cancer Group","volume":"13","author":"Finlay","year":"1995","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.005_bib5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/neuonc\/noq205","article-title":"Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the children\u2019s oncology group","volume":"13","author":"Cohen","year":"2011","journal-title":"Neuro-Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.005_bib6","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.hoc.2026.08.005_bib7","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.cell.2023.12.013","article-title":"Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective","volume":"187","author":"Mathur","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.005_bib8","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/s41467-023-36707-6","article-title":"Spatial transcriptomics reveals niche-specific enrichment and vulnerabilities of radial glial stem-like cells in malignant gliomas","volume":"14","author":"Ren","year":"2023","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.hoc.2026.08.005_bib9","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/s41588-022-01236-3","article-title":"The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location","volume":"54","author":"Liu","year":"2022","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.hoc.2026.08.005_bib10","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.ccell.2024.08.006","article-title":"GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant","volume":"42","author":"Liu","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2026.08.005_bib11","article-title":"Quantitative analysis of immune cells within the tumor microenvironment of glioblastoma and their relevance for prognosis","volume":"142","author":"Wang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.hoc.2026.08.005_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218216","article-title":"Tumor microenvironment in glioblastoma: the central role of the hypoxic\u2013necrotic core","volume":"639","author":"Bayona","year":"2026","journal-title":"Cancer Lett"},{"key":"10.1016\/j.hoc.2026.08.005_bib13","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3389\/fimmu.2018.01004","article-title":"Immune microenvironment in glioblastoma subtypes","volume":"9","author":"Chen","year":"2018","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.005_bib14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ccell.2024.03.013","article-title":"Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.005_bib15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ccell.2016.05.017","article-title":"The multifaceted role of perivascular macrophages in tumors","volume":"30","author":"Lewis","year":"2016","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.005_bib16","doi-asserted-by":"crossref","first-page":"937","DOI":"10.32604\/or.2024.056436","article-title":"Microglia and brain macrophages are differentially associated with tumor necrosis in glioblastoma: a link to tumor progression","volume":"33","author":"Loh","year":"2025","journal-title":"Oncol Res"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.005_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.immuni.2024.11.026","article-title":"Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion","volume":"58","author":"Waibl Polania","year":"2025","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.hoc.2026.08.005_bib18","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/neuonc\/nov280","article-title":"CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients","volume":"18","author":"Dubinski","year":"2016","journal-title":"Neuro-Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2026.08.005_bib19","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1158\/0008-5472.CAN-16-0144","article-title":"CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells","volume":"76","author":"Chang","year":"2016","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.005_bib20","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1186\/s12951-024-02888-5","article-title":"Hypoxic glioma-derived exosomal miR-25-3p promotes macrophage M2 polarization by activating the PI3K-AKT-mTOR signaling pathway","volume":"22","author":"Xue","year":"2024","journal-title":"J Nanobiotechnology"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.005_bib21","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12964-024-01523-y","article-title":"Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages","volume":"22","author":"Tankov","year":"2024","journal-title":"Cell Commun Signal"},{"issue":"2","key":"10.1016\/j.hoc.2026.08.005_bib22","doi-asserted-by":"crossref","first-page":"C487","DOI":"10.1152\/ajpcell.00124.2024","article-title":"Hypoxia conduces the glioma progression by inducing M2 macrophage polarization via elevating TNFSF9 level in a histone-lactylation-dependent manner","volume":"327","author":"Li","year":"2024","journal-title":"Am J Physiol-Cell Physiol"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.005_bib23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40478-018-0553-x","article-title":"Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma","volume":"6","author":"Lin","year":"2018","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"10.1016\/j.hoc.2026.08.005_bib24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ccell.2025.12.020","article-title":"IGSF11-VISTA is a critical and targetable immune checkpoint axis in diffuse midline glioma","volume":"44","author":"Collot","year":"2026","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.hoc.2026.08.005_bib25","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1016\/j.immuni.2024.09.007","article-title":"Microglia and monocyte-derived macrophages drive progression of pediatric high-grade gliomas and are transcriptionally shaped by histone mutations","volume":"57","author":"Ross","year":"2024","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.005_bib26","doi-asserted-by":"crossref","first-page":"7769","DOI":"10.1038\/s41467-024-52096-w","article-title":"Immune landscape of oncohistone-mutant gliomas reveals diverse myeloid populations and tumor-promoting function","volume":"15","author":"Andrade","year":"2024","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.hoc.2026.08.005_bib27","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ccell.2021.05.002","article-title":"Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma","volume":"39","author":"Hara","year":"2021","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.005_bib28","article-title":"The landscape of immune checkpoint inhibitor clinical trials in glioblastoma: a systematic review","volume":"6","author":"Schonfeld","year":"2024","journal-title":"Neuro-Oncol Adv"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.005_bib29","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41591-025-03512-1","article-title":"Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma","volume":"31","author":"Long","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.005_bib30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13046-019-1085-3","article-title":"Challenges and potential of PD-1\/PD-L1 checkpoint blockade immunotherapy for glioblastoma","volume":"38","author":"Wang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.hoc.2026.08.005_bib31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nop020","article-title":"MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma","volume":"12","author":"Rivera","year":"2010","journal-title":"Neuro-Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.08.005_bib32","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/neuonc\/noae058","article-title":"NRG-BN002: phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma","volume":"26","author":"Sloan","year":"2024","journal-title":"Neuro-Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2026.08.005_bib33","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1093\/neuonc\/noae135","article-title":"Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood\u2013brain barrier opening: a novel combinatorial immunotherapy regimen for gliomas","volume":"26","author":"Kim","year":"2024","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.hoc.2026.08.005_bib34","unstructured":"Wang M, Fu Y, Bom S, et al. Abstract citation ID: NOAF201.0494 CTIM-37. dual checkpoint blockade with anti-pd-1 and anti-lag-3 drives expansion and exhaustion of gzmk+ tumor-reactive t cell clones in glioblastoma."},{"key":"10.1016\/j.hoc.2026.08.005_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.637146","article-title":"TIGIT and PD-1 immune checkpoint pathways are associated with patient outcome and anti-tumor immunity in glioblastoma","volume":"12","author":"Raphael","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.005_bib36","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/med.70037","article-title":"Immunosuppressive tumor microenvironment and therapeutic landscape of diffuse intrinsic pontine glioma","volume":"46","author":"Zhou","year":"2026","journal-title":"Med Res Rev"},{"issue":"18","key":"10.1016\/j.hoc.2026.08.005_bib37","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.175257","article-title":"Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models","volume":"9","author":"Ausejo-Mauleon","year":"2024","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.hoc.2026.08.005_bib38","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1093\/neuonc\/noaf039","article-title":"Phase 1 dose-escalation trial using convection-enhanced delivery of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma","volume":"27","author":"Souweidane","year":"2025","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.hoc.2026.08.005_bib39","unstructured":"Antoku S, Xia S, Gundersen G, et al. Abstract citation id: noaf201.0285 cnsc-78. Nesprin-2 is upregulated in glioblastoma and contributes to tumor progression."},{"issue":"13","key":"10.1016\/j.hoc.2026.08.005_bib40","doi-asserted-by":"crossref","first-page":"14498","DOI":"10.1002\/cam4.6102","article-title":"Insights into the leveraging of GABAergic signaling in cancer therapy","volume":"12","author":"Li","year":"2023","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.hoc.2026.08.005_bib41","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41556-021-00820-9","article-title":"Cancer-cell-derived GABA promotes \u03b2-catenin-mediated tumour growth and immunosuppression","volume":"24","author":"Huang","year":"2022","journal-title":"Nat Cell Biol"},{"issue":"7885","key":"10.1016\/j.hoc.2026.08.005_bib42","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41586-021-04082-1","article-title":"B cell-derived GABA elicits IL-10+ macrophages to limit anti-tumour immunity","volume":"599","author":"Zhang","year":"2021","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.hoc.2026.08.005_bib43","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1073\/pnas.87.11.4207","article-title":"Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma","volume":"87","author":"Humphrey","year":"1990","journal-title":"Proc Natl Acad Sci"},{"issue":"8","key":"10.1016\/j.hoc.2026.08.005_bib44","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1349-7006.1990.tb02644.x","article-title":"A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors","volume":"81","author":"Yamazaki","year":"1990","journal-title":"Jpn J Cancer Res"},{"issue":"7","key":"10.1016\/j.hoc.2026.08.005_bib45","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1073\/pnas.89.7.2965","article-title":"Structural alterations of the epidermal growth factor receptor gene in human gliomas","volume":"89","author":"Wong","year":"1992","journal-title":"Proc Natl Acad Sci"},{"issue":"16","key":"10.1016\/j.hoc.2026.08.005_bib46","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1073\/pnas.91.16.7727","article-title":"A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity","volume":"91","author":"Nishikawa","year":"1994","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.005_bib47","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1158\/1078-0432.CCR-04-1737","article-title":"Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients","volume":"11","author":"Heimberger","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.hoc.2026.08.005_bib48","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2026.08.005_bib49","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1158\/1078-0432.CCR-18-1140","article-title":"Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-Expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial","volume":"26","author":"Reardon","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2026.08.005_bib50","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1084\/jem.20111424","article-title":"Autocrine VEGF\u2013VEGFR2\u2013Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth","volume":"209","author":"Hamerlik","year":"2012","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.hoc.2026.08.005_bib51","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2007.01.006","article-title":"Vascular endothelial growth factor (VEGF) signaling in tumor progression","volume":"62","author":"Roskoski","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/j.hoc.2026.08.005_bib52","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nrc3627","article-title":"VEGF targets the tumour cell","volume":"13","author":"Goel","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"30","key":"10.1016\/j.hoc.2026.08.005_bib53","doi-asserted-by":"crossref","first-page":"21569","DOI":"10.18632\/oncotarget.25131","article-title":"A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent\/progressive high grade glioma","volume":"9","author":"Shibao","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.005_bib54","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12885-020-6589-x","article-title":"Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series","volume":"20","author":"Tamura","year":"2020","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.005_bib55","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2176\/nmc.47.165","article-title":"Expression of WT1 protein and correlation with cellular proliferation in glial tumors","volume":"47","author":"Hashiba","year":"2007","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"38","key":"10.1016\/j.hoc.2026.08.005_bib56","doi-asserted-by":"crossref","first-page":"13885","DOI":"10.1073\/pnas.0405884101","article-title":"Induction of WT1 (wilms\u2019 tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression","volume":"101","author":"Oka","year":"2004","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"10.1016\/j.hoc.2026.08.005_bib57","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3171\/JNS\/2008\/108\/5\/0963","article-title":"Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme","volume":"108","author":"Izumoto","year":"2008","journal-title":"J Neurosurg"},{"issue":"8","key":"10.1016\/j.hoc.2026.08.005_bib58","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm0897-917","article-title":"A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma","volume":"3","author":"Ambrosini","year":"1997","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.005_bib59","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1200\/JCO.2002.20.4.1063","article-title":"Quantitatively determined survivin expression levels are of prognostic value in human gliomas","volume":"20","author":"Chakravarti","year":"2002","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.005_bib60","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/cncr.11122","article-title":"Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis","volume":"97","author":"Kajiwara","year":"2003","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2026.08.005_bib61","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00262-010-0845-x","article-title":"Antitumor cytotoxic T-cell response induced by a survivin peptide mimic","volume":"59","author":"Ciesielski","year":"2010","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"10.1016\/j.hoc.2026.08.005_bib62","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO.22.00996","article-title":"Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma","volume":"41","author":"Ahluwalia","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2026.08.005_bib63","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1172\/JCI140378","article-title":"Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma","volume":"130","author":"Mueller","year":"2020","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.hoc.2026.08.005_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005535","article-title":"H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma","volume":"10","author":"Immisch","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2026.08.005_bib65","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/s41591-023-02555-6","article-title":"A H3K27M-targeted vaccine in adults with diffuse midline glioma","volume":"29","author":"Grassl","year":"2023","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.hoc.2026.08.005_bib66","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"issue":"7854","key":"10.1016\/j.hoc.2026.08.005_bib67","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-021-03363-z","article-title":"A vaccine targeting mutant IDH1 in newly diagnosed glioma","volume":"592","author":"Platten","year":"2021","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.hoc.2026.08.005_bib68","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/brain\/aws042","article-title":"Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy","volume":"135","author":"Dutoit","year":"2012","journal-title":"Brain"},{"issue":"19","key":"10.1016\/j.hoc.2026.08.005_bib69","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1158\/1078-0432.CCR-16-0506","article-title":"A cancer research UK first time in human phase I trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma","volume":"22","author":"Rampling","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.hoc.2026.08.005_bib70","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/neuonc\/noz040","article-title":"Phase I\/II trial testing safety and immunogenicity of the multipeptide IMA950\/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients","volume":"21","author":"Migliorini","year":"2019","journal-title":"Neuro-Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.08.005_bib71","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2174\/1381612053507620","article-title":"Autologous formalin-fixed tumor vaccine","volume":"11","author":"Ohno","year":"2005","journal-title":"Curr Pharm Des"},{"issue":"3","key":"10.1016\/j.hoc.2026.08.005_bib72","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3171\/2014.5.JNS132392","article-title":"Phase I\/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma: clinical article","volume":"121","author":"Ishikawa","year":"2014","journal-title":"J Neurosurg"},{"issue":"2","key":"10.1016\/j.hoc.2026.08.005_bib73","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3171\/2022.12.JNS221221","article-title":"A multicenter, randomized, placebo-controlled phase IIb trial of an autologous formalin-fixed tumor vaccine for newly diagnosed glioblastomas","volume":"139","author":"Muragaki","year":"2023","journal-title":"J Neurosurg"},{"issue":"8","key":"10.1016\/j.hoc.2026.08.005_bib74","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2001.19.8.2189","article-title":"Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas","volume":"19","author":"Andrews","year":"2001","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.005_bib75","doi-asserted-by":"crossref","DOI":"10.29046\/JHNJ.013.1.002","article-title":"Phase 1 trial of vaccination with autologous tumor cells and antisense directed against the insulin growth factor type 1 receptor (IGF-1R AS ODN) in patients with recurrent glioblastoma","volume":"13","author":"Andrews","year":"2018","journal-title":"JHN J"},{"issue":"7","key":"10.1016\/j.hoc.2026.08.005_bib76","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1158\/1078-0432.CCR-20-3805","article-title":"Phase Ib clinical trial of IGV-001 for patients with newly diagnosed glioblastoma","volume":"27","author":"Andrews","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.hoc.2026.08.005_bib77","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7812\/TPP\/14-042","article-title":"Use of ERC-1671 vaccine in a patient with recurrent glioblastoma multiforme after progression during bevacizumab therapy: first published report","volume":"19","author":"Bota","year":"2015","journal-title":"Perm J"},{"issue":"3","key":"10.1016\/j.hoc.2026.08.005_bib78","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11060-016-2245-3","article-title":"Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study","volume":"130","author":"Pollack","year":"2016","journal-title":"J Neurooncol"},{"issue":"3","key":"10.1016\/j.hoc.2026.08.005_bib79","doi-asserted-by":"crossref","DOI":"10.2217\/cns-2018-0009","article-title":"Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts","volume":"7","author":"Bota","year":"2018","journal-title":"CNS Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.005_bib80","doi-asserted-by":"crossref","first-page":"6870","DOI":"10.1038\/s41467-024-51315-8","article-title":"A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine","volume":"15","author":"Latzer","year":"2024","journal-title":"Nat Commun"},{"issue":"7738","key":"10.1016\/j.hoc.2026.08.005_bib81","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.005_bib82","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.08.005_bib83","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1002\/stem.102","article-title":"Antigen-specific T-Cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens","volume":"27","author":"Xu","year":"2009","journal-title":"Stem Cells"},{"issue":"1","key":"10.1016\/j.hoc.2026.08.005_bib84","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00262-012-1319-0","article-title":"Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma","volume":"62","author":"Phuphanich","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"10.1016\/j.hoc.2026.08.005_bib85","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.cell.2024.04.003","article-title":"RNA aggregates harness the danger response for potent cancer immunotherapy","volume":"187","author":"Mendez-Gomez","year":"2024","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.hoc.2026.08.005_bib86","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011817","article-title":"Systemic mRNA vaccines elicit rapid immune activation in canine brain tumors","volume":"13","author":"Carrera-Justiz","year":"2025","journal-title":"J Immunother Cancer"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826001061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826001061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:50:51Z","timestamp":1791316251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826001061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":86,"alternative-id":["S0889858826001061"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.08.005","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brain Tumor Vaccines","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}